Vera Therapeutics Q3 EPS misses estimates

Vera Therapeutics

05/11/2025 12:36

Overview

Vera Therapeutics Q3 net loss and EPS miss analyst expectations

Company expects BLA submission for atacicept in Q4 2025

Vera maintains strong cash position, funding operations through potential atacicept launch

Outlook

Company expects to submit BLA for atacicept to FDA in Q4 2025

Vera anticipates potential U.S. launch of atacicept in 2026

Company expects initial PIONEER trial results in Q4 2025

Result Drivers

CLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for atacicept

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Miss
-$1.26
-$1.13 (12 Analysts)
Q3 Net Income
Miss
-$80.29 mln
-$75.26 mln (10 Analysts)
Q3 Operating Income
Miss
-$83.93 mln
-$75.62 mln (11 Analysts)
Q3 Operating Expenses
$83.93 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vera Therapeutics Inc is $60.00, about 59.4% above its November 4 closing price of $24.35

Press Release: ID:nGNX7LgC7F

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)